US-based Arch Therapeutics has signed a distribution agreement with Centurion Therapeutics to expand access to its AC5 Advanced Wound System.
Centurion delivers a portfolio of aseptically processed human tissues through contracted wound care distributors.
As part of the distribution deal, Arch Therapeutics’s AC5 Advanced Wound System will now be added to Centurion’s advanced wound care product line.
Arch Therapeutics Sales vice-president Dan Yrigoyen said: “Partnering with Centurion supports our strategic plan to expand AC5 Advanced Wound System into non-government US-based hospitals.
“The agreement complements our current focus of selling to government hospitals across the country and expands our sales footprint within key selling channels.
“We remain committed to providing improved outcomes for patients with acute and chronic wounds, and the partnership with Centurion is an exciting and important development in support of our overall commercialisation plan.”
AC5 Advanced Wound System is an adaptive self-assembling barrier scaffold (aSABS) and peptide technology with distinctive utility across all phases of wound healing.
It is used to manage partial and full-thickness wounds, such as diabetic foot ulcers, venous leg ulcers, pressure sores and surgical wounds.
The US Food and Drug Administration (FDA) granted marketing authorisation to the system.
Centurion is an exclusive strategic partner to the largest tissue bank in the world.
In January, Arch announced that the AC5 Advanced Wound System demonstrated clinical benefit in patients with nonhealing wounds and significant comorbidities in a study.
It also showed improvement in healing after three to six applications, with weekly clinic visits and reapplications.